According to a report from Benzinga on May 30th, the Health Department of Costa Rica has issued resolution number MS-DM-RC-2381-2024, which prohibits the import, sale, and commercialization of e-cigarettes and related products, specifically e-liquid products containing synthetic nicotine or cannabinoids.
This preventive measure has sparked discussions and reactions within the affected industry. The ban went into effect immediately after its announcement and will remain in place until the Ministry of Health releases technical regulations regarding the use and commercialization of these products.
In 2022, Bill 10.113 was passed, allowing for the import and use of cannabis products for medical and therapeutic purposes, as well as for the use of cannabis in food and industrial applications.
According to reports, the e-cigarette market in Costa Rica is still in its developmental stage. The ban has changed the business and entrepreneurial landscape for the industry, potentially causing losses for those involved and requiring the Ministry of Health to introduce clear new guidelines.
According to industry experts in Costa Rica, the decision requires additional technical regulation beyond what is established in Law No. 10.113. This means that while the importation of marijuana products is allowed, the use of consumption devices is not permitted until new standards are set.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
